论文部分内容阅读
目的观察克林霉素联合氨曲南治疗盆腔炎性疾病(pelvic inflammatory disease,PID)的临床疗效及安全性。方法将2009年12月至2011年12月来郫县计划生育服务站就诊的234例PID患者随机分为两组,观察组118例选用克林霉素联合氨曲南治疗,对照组116例给予左氧氟沙星联合甲硝唑治疗,观察两组疗效及安全性。结果观察组痊愈111例(94.07%),对照组痊愈85例(73.28%);总有效率观察组为97.46%(115/118),对照组为87.93%(102/116),两组比较差异有统计学意义(P<0.05)。不良反应发生率观察组3.39%(4/118),对照组12.07%(14/116),两组均无严重不良反应。结论克林霉素联合氨曲南治疗PID能提高临床疗效,减少不良反应的发生,值得临床推广应用。
Objective To observe the clinical efficacy and safety of clindamycin and aztreonam in the treatment of pelvic inflammatory disease (PID). Methods A total of 234 PID patients from December 2009 to December 2011 who came to the family planning service station in Yuxian County were randomly divided into two groups. 118 cases in the observation group were treated with clindamycin and aztreonam, while 116 in the control group Levofloxacin combined with metronidazole treatment, efficacy and safety were observed in both groups. Results The observation group recovered 111 cases (94.07%), the control group recovered 85 cases (73.28%); the total effective rate observation group was 97.46% (115/118), the control group was 87.93% (102/116) There was statistical significance (P <0.05). The incidence of adverse reactions was 3.39% (4/118) in the observation group and 12.07% (14/116) in the control group, with no serious adverse reactions in both groups. Conclusion Clindamycin combined with aztreonam in the treatment of PID can improve the clinical curative effect and reduce the occurrence of adverse reactions, which is worthy of clinical application.